H.C. Wainwright Maintains a Buy Rating on Second Sight Medical Products

H.C. Wainwright analyst Amit Dayal maintained a Buy rating on Second Sight Medical Products (NASDAQ: EYES) today and set a price target of $5. The company’s shares closed yesterday at $1.95.

According to TipRanks.com, Dayal is a 1-star analyst with an average return of 0.0% and a 41.3% success rate. Dayal covers the Consumer Goods sector, focusing on stocks such as Superconductor Technologies Inc, Pacific Ethanol, and Marrone Bio.

Second Sight Medical Products has an analyst consensus of Moderate Buy, with a price target consensus of $5.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.58 and a one-year low of $0.90. Currently, Second Sight Medical Products has an average volume of 437.2K.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EYES in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Second Sight Medical Products, Inc. creates a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations such as Retinitis Pigmentosa. It develops, manufactures and market implantable visual prosthetics to enable blind individuals to overcome disability and achieve greater independence.